Monitor for any future amendments to this 13D that signal a shift from passive insider ownership to activist intent, such as demands for board seats or strategic changes. The lock-up expiration in ~April 2027 is a key date for potential share sales.
Price Chart
Executive Summary
CEO and co-founder Eric Keller filed a Schedule 13D disclosing beneficial ownership of 598,598 shares (7.07% of outstanding common stock) of Retension Pharmaceuticals, Inc. The filing is a routine insider ownership disclosure triggered by the company's IPO on October 13, 2026, and the conversion of preferred shares into common stock. No activist intent or change in control strategy is indicated.
Key Financial Metrics
Key Facts
- Eric Keller beneficially owns 598,598 shares of common stock, representing 7.07% of shares outstanding post-IPO.
- The filing is a Schedule 13D, not a 13G, because Keller is an executive officer and director, not a passive investor.
- Keller purchased 20,800 shares at $12.00/share in the IPO on October 13, 2026, for $249,600.
- A 1-for-6.21 reverse stock split was effected on October 2, 2026, and all preferred shares converted to common at the IPO closing.
- Keller is subject to a 180-day lock-up agreement with underwriters Leerink Partners and Guggenheim Securities.
- Keller's stated purpose is investment and compensation; no plans for board changes, sale, or other Item 4 actions are disclosed.
Financial Impact
No material financial impact; the filing is a routine ownership disclosure post-IPO.
Risk Factors
- Insider selling after lock-up expiration could pressure the stock.
- No activist catalyst is present; the filing is purely informational.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D Filing (Primary) | 0001213900-26-109425 |
| Document: 0001213900-26-109425-index.html | 0001213900-26-109425 |
| Document: 0001213900-26-109425.txt | 0001213900-26-109425 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $15.25 | awaiting T+5 | — | $14.10 (−7.54%) |
Oct 16, 2026 10d ago | SC 13G | $16.33 $14.65 | ▼ −10.29% | ▼ −10.14% | $14.10 (−13.66%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.10 (+0.21%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.10 (+15.48%) |
Oct 14, 2026 12d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.10 (+15.48%) |
Oct 13, 2026 13d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.10 (+21.13%) |
Oct 13, 2026 13d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.10 (+21.13%) |
Oct 9, 2026 17d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.10 (+24.56%) |
Oct 9, 2026 18d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.10 (+33.90%) |
Oct 8, 2026 18d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.10 (+33.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers